A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome

Inclusion Criteria: * Age ≥18 years old, male or female; * Diagnosis of POEMS syndrome with relapsed or refractory disease; * Eastern Cooperative Oncology Group (ECOG) Performance ≤2 ; * Adequate venous access for the apheresis of peripheral blood mononuclear cell; * Vascular Endothelial Growth Factor (VEGF) ≥1200ng/L； * Overall Neuropathy Limitations Scale (ONLS) ≥ 1; * Adequate organ function; * Able and willing to comply with the study protocol and follow-up plan, and sign the informed consent form in writing. Exclusion Criteria: * Subjects who had previously received BCMA-CD19 dual-target CAR-T cell products or autologous stem cell transplantation within 12 weeks before the collection of peripheral blood mononuclear cells; * Known allergy or hypersensitivity reactions to cyclophosphamide, fludarabine, dimethyl sulfoxide (DMSO), CD19, or BCMA-targeted drugs; * Received any treatment that might influence the activity of CAR-T cells prior to the collection of peripheral blood mononuclear cells; * Have history of vaccination within the 4 weeks preceding the collection of peripheral blood mononuclear cells; * Have tested positive for cytomegalovirus and/or mycobacterium tuberculosis, or had any uncontrolled active infection within 14 days prior to the collection of peripheral blood mononuclear cells; * Subjects infected with active HBV or HCV, HIV, syphilis; * Subjects with known central nervous system disease, for example, seizure disorders, clinically significant cerebral…